share_log

Allarity Therapeutics | 10-Q: Q2 2024 Earnings Report

Allarity Therapeutics | 10-Q: Q2 2024 Earnings Report

Allarity Therapeutics | 10-Q:2024財年二季報
美股SEC公告 ·  08/05 17:27

Moomoo AI 已提取核心訊息

Allarity Therapeutics, Inc. (Allarity), a clinical-stage pharmaceutical company, reported its financial performance for the quarter ended June 30, 2024. The company experienced a net loss of $1.629 million for the quarter, a decrease from the $2.380 million loss in the same period the previous year. Research and development expenses slightly decreased by $47 thousand year-on-year to $1.058 million, while general and administrative expenses saw a more significant drop of $738 thousand to $2.313 million. The decrease in general and administrative expenses was attributed to cost-cutting measures, including reduced staffing costs. Other income for the quarter was $1.742 million, primarily due to a fair value adjustment to derivative liabilities. For the six-month period, the net loss was $5.476 million, a slight improvement from the $5.732 million loss...Show More
Allarity Therapeutics, Inc. (Allarity), a clinical-stage pharmaceutical company, reported its financial performance for the quarter ended June 30, 2024. The company experienced a net loss of $1.629 million for the quarter, a decrease from the $2.380 million loss in the same period the previous year. Research and development expenses slightly decreased by $47 thousand year-on-year to $1.058 million, while general and administrative expenses saw a more significant drop of $738 thousand to $2.313 million. The decrease in general and administrative expenses was attributed to cost-cutting measures, including reduced staffing costs. Other income for the quarter was $1.742 million, primarily due to a fair value adjustment to derivative liabilities. For the six-month period, the net loss was $5.476 million, a slight improvement from the $5.732 million loss in the prior year. The company's cash and cash equivalents stood at $19.233 million as of June 30, 2024. Allarity's business development has been marked by its focus on advancing its lead drug candidate, Stenoparib, through clinical trials. The company's future plans include continuing clinical development efforts and seeking additional funding through equity offerings or other sources to support its operations and development programs. Allarity has also been involved in an SEC investigation related to its disclosures regarding FDA meetings, and it received a Wells Notice indicating a preliminary determination to recommend enforcement action. The company is cooperating with the SEC and intends to respond formally to the notice. Additionally, Allarity is addressing a Nasdaq delisting notification due to non-compliance with the minimum bid price requirement.
臨床階段製藥公司Allarity Therapeutics,Inc. (Allarity)已公佈2024年6月30日結束季度的財務業績。本季度公司淨虧損爲162.9萬美元,較去年同期的238萬美元虧損有所下降。研發費用與去年同期相比略微減少了4.7萬美元,至105.8萬美元,而一般和管理費用則大幅下降了73.8萬美元,至231.3萬美元。一般和管理費用的下降歸因於採取的削減成本措施,包括減少員工成本。本季度其他收入爲174.2萬美元,主要是由於衍生負債的公允價值調整。這六個月期間,淨虧損爲547.6萬美元,略有改善,去年同期爲573.2萬美元的虧損。截至2024年6月30日,該公司的現金及現金...展開全部
臨床階段製藥公司Allarity Therapeutics,Inc. (Allarity)已公佈2024年6月30日結束季度的財務業績。本季度公司淨虧損爲162.9萬美元,較去年同期的238萬美元虧損有所下降。研發費用與去年同期相比略微減少了4.7萬美元,至105.8萬美元,而一般和管理費用則大幅下降了73.8萬美元,至231.3萬美元。一般和管理費用的下降歸因於採取的削減成本措施,包括減少員工成本。本季度其他收入爲174.2萬美元,主要是由於衍生負債的公允價值調整。這六個月期間,淨虧損爲547.6萬美元,略有改善,去年同期爲573.2萬美元的虧損。截至2024年6月30日,該公司的現金及現金等價物爲1923.3萬美元。Allarity的業務發展以推進其領先藥物候選品Stenoparib的臨床試驗爲標誌。公司未來計劃包括持續開展臨床研發工作,並通過股票發行或其他渠道尋求額外資金來支持其運營和發展計劃。Allarity還涉及美國證券交易委員會(SEC)與其關於FDA會議披露的調查,並收到了預作出執行行動建議的Wells通知。公司正在配合SEC,打算對通知做出正式回應。此外,Allarity還因不符合最低買盤價格要求而收到了Nasdaq的退市通知。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息